Product Name :
PD-166793
Description:
PD-166793 is a potent, selective, orally active and wide‐broad spectrum inhibitor of MMP, exhibiting nanomolar potency against MMP-2, MMP-3 and MMP-13 (IC50=4, 7, and 8 nM, respectively) and micromolar potency vs MMP-1, -7 and -9 (IC50=6.0, 7.2, and 7.9 μM, respectively). PD-166793 can attenuate left ventricular remodeling and dysfunction in a rat model of progressive heart failure.
CAS:
199850-67-4
Molecular Weight:
412.30
Formula:
C17H18BrNO4S
Chemical Name:
2-4′-bromo-[1,1′-biphenyl]-4-sulfonamido-3-methylbutanoic acid
Smiles :
CC(C)C(NS(=O)(=O)C1=CC=C(C=C1)C1=CC=C(Br)C=C1)C(O)=O
InChiKey:
GJOCABIDMCKCEG-UHFFFAOYSA-N
InChi :
InChI=1S/C17H18BrNO4S/c1-11(2)16(17(20)21)19-24(22,23)15-9-5-13(6-10-15)12-3-7-14(18)8-4-12/h3-11,16,19H,1-2H3,(H,20,21)
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.Ofloxacin manufacturer
Shelf Life:
≥12 months if stored properly.Lacidipine In Vitro
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.PMID:34896717
Additional information:
PD-166793 is a potent, selective, orally active and wide‐broad spectrum inhibitor of MMP, exhibiting nanomolar potency against MMP-2, MMP-3 and MMP-13 (IC50=4, 7, and 8 nM, respectively) and micromolar potency vs MMP-1, -7 and -9 (IC50=6.0, 7.2, and 7.9 μM, respectively). PD-166793 can attenuate left ventricular remodeling and dysfunction in a rat model of progressive heart failure.|Product information|CAS Number: 199850-67-4|Molecular Weight: 412.30|Formula: C17H18BrNO4S|Chemical Name: 2-4′-bromo-[1,1′-biphenyl]-4-sulfonamido-3-methylbutanoic acid|Smiles: CC(C)C(NS(=O)(=O)C1=CC=C(C=C1)C1=CC=C(Br)C=C1)C(O)=O|InChiKey: GJOCABIDMCKCEG-UHFFFAOYSA-N|InChi: InChI=1S/C17H18BrNO4S/c1-11(2)16(17(20)21)19-24(22,23)15-9-5-13(6-10-15)12-3-7-14(18)8-4-12/h3-11,16,19H,1-2H3,(H,20,21)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 100 mg/mL (242.54 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|PD-166793 (0.1 μM) leads to a 20% inhibition of AMP deaminase (AMPD) activity in rat heart homogenates. PD-166793 (100 μM; 36 h) significantly reduces MMP‐9 activity in normal human cardiac fibroblasts.|In Vivo:|PD-166793 (1 mg/kg/d; daily gavage for 10 weeks) largely prevents the adverse remodeling characteristically seen in the aortocaval (AV) fistula model. PD-166793 (5 mg/kg; oral gavage) exhibits superior pharmacokinetics (t1/2=43.6 h, Cmax=42.4 µg/mL, AUC0-∞=2822 µg•h/mL) in rats.|Products are for research use only. Not for human use.|
